The Science
The Science
Regenerative therapy operates at the cellular level — not to mask the symptoms of disease or injury, but to address the underlying breakdown of tissue and function that causes them. By introducing specialized biological agents into damaged areas of the body, regenerative therapy activates and amplifies the body's innate capacity to rebuild, repair, and restore.
This approach represents a fundamental shift in medical philosophy: rather than managing chronic conditions indefinitely, regenerative medicine aims to give clinicians tools that may actually reverse the damage driving those conditions. Advances in biomedical science over the past two decades have accelerated this field dramatically, moving it from the laboratory into active clinical practice across orthopedics, cardiology, neurology, immunology, and beyond.
At Genova Biologix, we are at the forefront of this movement — providing physicians with the highest-quality umbilical cord allograft products to deliver these therapies safely, consistently, and effectively.
How It Works
Cellular allografts derived from umbilical cord tissue are considered "naïve" — meaning they are unspecialized and responsive to environmental cues. When introduced into areas of damaged tissue, these cells have a remarkable ability to differentiate and take on context-specific functions, potentially repairing or compensating for cells that have been lost to injury, disease, or degeneration.
Because this is a minimally invasive process that works with the body's existing biology rather than against it, regenerative therapy offers the possibility of meaningful clinical benefit while avoiding the risks and recovery associated with more invasive interventions.
Mesenchymal Stem Cells
Hover over each card to learn more
Product Origins
Regenerative cells can be derived from several biological sources, each with distinct characteristics. Genova Biologix exclusively uses umbilical cord-derived products — and for good reason.
Collected immediately after birth from consenting donors, umbilical cord tissue is ethically sound, non-invasive to retrieve, and yields the highest concentration of growth factors, cytokines, and regenerative cells of any available source. It is the gold standard for allograft biologics — and the exclusive source for all Genova Biologix products.
While widely studied, bone marrow-derived cells require an invasive harvesting procedure under anesthesia, yield relatively lower cell concentrations, and are subject to age-related decline in donor quality. Autologous approaches also limit scalability and consistency of product.
Fat-derived regenerative cells require liposuction for retrieval and contain significantly fewer MSCs per volume than cord tissue. Their growth factor profile is also less robust, making them a less optimal source for high-potency therapeutic applications.
Embryonic stem cells carry significant ethical concerns due to the destruction of embryos in the harvesting process. Regulatory restrictions and public scrutiny have limited their clinical adoption, and Genova Biologix does not use embryonic-derived products in any of its formulations.
Ready to Learn More?
The science of regenerative therapy is backed by a growing body of peer-reviewed research. Explore the studies that inform our approach — and discover how Genova Biologix products are helping clinicians deliver better patient outcomes.
